Country for PR: United States
Contributor: PR Newswire New York
Wednesday, January 18 2023 - 10:00
AsiaNet
Suvoda 2022 Clinical Trials Surge 20% as it Expands Offerings to Include eConsent and eCOA
PHILADELPHIA, Jan. 18, 2023 /PRNewswire-AsiaNet/ --

-- Company achieves Top Performer status in ISR IRT Benchmark Survey

Suvoda LLC ( 
https://c212.net/c/link/?t=0&l=en&o=3756407-1&h=3282413622&u=https%3A%2F%2Fwww.suvoda.com%2F%3Futm_medium%3Dpress-release%26utm_source%3Dpress-release%26utm_campaign%3Dmomentum-release-2023%26utm_content%3Dpress-release-momentum-2023-01&a=Suvoda+LLC 
) , a global clinical trial technology company that specializes in complex 
studies in therapeutic areas like oncology, central nervous system (CNS), and 
rare disease, surpassed 1,000 clinical trials in 2022 as study deployments 
surged nearly 20%, a strong indicator that the company's practical approach to 
innovation is being embraced by trial sponsors and CROs. Click to tweet ( 
https://c212.net/c/link/?t=0&l=en&o=3756407-1&h=1775877916&u=https%3A%2F%2Fctt.ac%2Fpg87j&a=Click+to+tweet 
) .

Logo - https://mma.prnewswire.com/media/1759317/Suvoda_Logo.jpg 

Suvoda's expanded clinical trial offerings in 2022 were designed organically to 
work seamlessly on a single platform, and include important features that 
sponsors need to quickly and reliably conduct trials. New products and features 
include:

    -- eConsent ( 
https://c212.net/c/link/?t=0&l=en&o=3756407-1&h=174185347&u=https%3A%2F%2Fwww.suvoda.com%2Finsights%2Fall-news%2Feconsent-press-release%3Futm_medium%3Dpress-release%26utm_source%3Dpress-release%26utm_campaign%3Dmomentum-release-2023%26utm_content%3Dpress-release-momentum-2023-01&a=eConsent 
) –Suvoda eConsent, which became generally available 
       in May, offers a simplified approach to digitizing the consent 
management 
       process. Built on the Suvoda platform, Suvoda eConsent gives sponsors, 
       CROs, and sites improved visibility and automated control of consent 
       throughout the life of a trial and peace of mind that patient data is 
       secure, compliant, and available at the moment of signature without 
       disrupting existing processes.

    -- Free picking ( 
https://c212.net/c/link/?t=0&l=en&o=3756407-1&h=3898958288&u=https%3A%2F%2Fwww.suvoda.com%2Finsights%2Fall-news%2Fsuvoda-announces-free-picking-clinical-trial-distribution%3Futm_medium%3Dpress-release%26utm_source%3Dpress-release%26utm_campaign%3Dmomentum-release-2023%26utm_content%3Dpress-release-momentum-2023-01&a=Free+picking 
) —This new 
       IRT functionality gives sponsors more flexibility in managing their 
       supply-side packaging, labeling, and distribution operations, empowering 
       them to effectively and safely transition to a Just-in-Time (JIT) 
       paradigm.  

    -- Electronic clinical outcome assessment (eCOA) ( 
https://c212.net/c/link/?t=0&l=en&o=3756407-1&h=2719518503&u=https%3A%2F%2Fwww.suvoda.com%2Finsights%2Fall-news%2Fsuvoda-launches-ecoa-design-toolkit%3Futm_medium%3Dpress-release%26utm_source%3Dpress-release%26utm_campaign%3Dmomentum-release-2023%26utm_content%3Dpress-release-momentum-2023-01&a=Electronic+clinical+outcome+assessment+(eCOA) 
) --Suvoda eCOA 
       seeks to tackle inefficiencies common in traditional eCOA products, such 
       as gaps in overall delivery and execution quality, time-consuming 
       translations and localization processes, and logistics related to device 
       management. In December the company released a unique, easy-to-use, 
       configuration-based toolkit designed to simplify and accelerate eCOA 
set- 
       up and delivery while the product entered the second phase of the early 
       adopter program.

"Trial sponsors and CROs have told us they need new approaches to global 
clinical trials with patients at the center of the studies, and we have 
listened," said Jagath Wanninayake, CEO of Suvoda. "We have been assembling the 
building blocks of a new platform that simplifies the complexity inherent in 
these trials, while also investing in our people. We are seeing the fruit of 
that labor with increased study deployments and excellent industry rankings. 
2023 will be an exciting year as we continue building to realize our vision."

Suvoda was ranked among the top three IRT providers in the recent ISR IRT 
Benchmark Survey, another indication that the company's product roadmap is 
meeting the needs of study sponsors, CROs and sites.

In the ISR IRT Benchmark Survey, Suvoda scored above average or outperformed 
competitors in nine of 12 key areas assessed, including the categories most 
important to drug trial sponsors: integration with EDC, ePRO, CTMS, and other 
data systems; flexibility for mid-study design changes; speed of data 
integration; and configurability in study set-up.

The ISR Benchmark Survey also ranked Suvoda one of the highest among all 
vendors for customer loyalty, which reflects similar results achieved in 
Suvoda's customer satisfaction survey ( 
https://c212.net/c/link/?t=0&l=en&o=3756407-1&h=809326933&u=https%3A%2F%2Fwww.suvoda.com%2Finsights%2Fblog%2Firt-customer-satisfaction%3Futm_medium%3Dpress-release%26utm_source%3Dpress-release%26utm_campaign%3Dmomentum-release-2023%26utm_content%3Dpress-release-momentum-2023-01&a=+customer+satisfaction+survey 
) , which found that 92% of customers are likely to recommend Suvoda to 
colleagues.

In 2022, Suvoda continued to expand its global presence, now supporting trials 
in nearly 80 countries and adding talent at all levels across the globe, 
bringing the total number to almost 900 employees. The company made important 
hires, including industry luminaries and technology executives ( 
https://c212.net/c/link/?t=0&l=en&o=3756407-1&h=2850648487&u=https%3A%2F%2Fwww.suvoda.com%2Finsights%2Fall-news%2Fnew-leadership-team-driving-further-product-innovation%3Futm_medium%3Dpress-release%26utm_source%3Dpress-release%26utm_campaign%3Dmomentum-release-2023%26utm_content%3Dpress-release-momentum-2023-01&a=technology+executives 
)  with proven experience building extensible and scalable solutions who are 
working closely with Suvoda's eClinical experts to design innovative, yet 
practical solutions that manage the increasing complexities of global clinical 
trials.

"We expect 2023 to continue to be challenging for clinical trial sponsors as 
financial markets tighten and sponsors face pressure to initiate trials 
quickly, show progress early, and execute flawlessly," said Suvoda's Chief 
Operating Officer Robert Hummel. "Suvoda is building a platform that helps 
reduce these risks for sponsors while also keeping the patient central to the 
mission by making it easier for them to participate in trials. In the end, our 
goal is to help sponsors develop therapies for patients who need them most."

About Suvoda

Suvoda is a global clinical trial technology company specializing in complex, 
life-sustaining studies in therapeutic areas like oncology, central nervous 
system (CNS), and rare disease. Founded in 2013 by experts in eClinical 
technologies, Suvoda empowers clinical trial professionals to manage the most 
urgent moments in the most urgent trials through advanced software solutions 
delivered on a single platform. Headquartered outside Philadelphia, Suvoda also 
maintains offices in Portland, OR, Barcelona, Spain, Bucharest, Romania, and 
Tokyo, Japan. The company consistently boasts a Net Promoter Score (NPS) of 
close to 70, far exceeding the technology industry average of 50, and has been 
selected by trial sponsors and CROs to support more than 1,000 trials across 80 
countries. To learn more, visit suvoda.com ( 
https://c212.net/c/link/?t=0&l=en&o=3756407-1&h=1437926295&u=https%3A%2F%2Fwww.suvoda.com%2F%3Futm_medium%3Dpress-release%26utm_source%3Dpress-release%26utm_campaign%3Dmomentum-release-2023%26utm_content%3Dpress-release-momentum-2023-01&a=suvoda.com 
) . Follow Suvoda on Twitter ( 
https://c212.net/c/link/?t=0&l=en&o=3756407-1&h=4068859578&u=https%3A%2F%2Ftwitter.com%2FSuvodaIRT&a=Twitter 
)  and LinkedIn ( 
https://c212.net/c/link/?t=0&l=en&o=3756407-1&h=1591256008&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsuvoda&a=LinkedIn 
) . 

For information contact:

Mara Conklin, (847) 340-6823
mconklin@teamclarus.com

Kathy Zoeller, (312) 485-2422
kathy@mattsonpr.com
 
SOURCE Suvoda LLC
Translations

Japanese